sorafenib has been researched along with cucurbitacin b in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (cucurbitacin b) | Trials (cucurbitacin b) | Recent Studies (post-2010) (cucurbitacin b) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 176 | 0 | 130 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, Y; Li, D; Li, H; Li, J; Liu, J; Liu, W; Shi, M; Wang, X; Xu, C; Yan, X; Yang, T; Zhang, T; Zhang, Y; Zhao, R | 1 |
1 other study(ies) available for sorafenib and cucurbitacin b
| Article | Year |
|---|---|
Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Drug Synergism; Female; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Phosphorylation; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Triterpenes; Xenograft Model Antitumor Assays | 2021 |